Development of potent selective competitive-antagonists of the melanocortin type 2 receptor
Cushing's disease, a hypercortisolemic state induced by an ACTH overexpressing pituitary adenoma, causes increased morbidity and mortality. Selective antagonism of the melanocortin type 2 receptor (MC2R) may be a novel treatment modality. Five structurally related peptides with modified HFRW sites but intact putative MC2R binding sites were tested for antagonistic activity at MC1R, MC2R/MRAP, MC3R, MC4R and MC5R. Two of these peptides (GPS1573 and GPS1574) dose-dependently antagonized ACTH-stimulated MC2R activity (IC50s of 66±23nM and 260±1nM, respectively). GPS1573 and 1574 suppressed the Rmax but not EC50 of ACTH on MC2R, indicating non-competitive antagonism. These peptides did not antagonize α-MSH stimulation of MC1R and antagonized MC3, 4 and 5R at markedly lower potency. GP1573 and GPS1574 antagonize MC4R with IC50s of 950nM and 3.7μM, respectively. In conclusion, two peptide antagonists were developed with selectivity for MC2R, forming a platform for development of a medical treatment for Cushing's disease.
|Keywords||Melanocortin 2 receptor (MC2R)|
|Persistent URL||dx.doi.org/10.1016/j.mce.2014.07.003, hdl.handle.net/1765/61084|
|Journal||Molecular and Cellular Endocrinology|
Bouw, E, Huisman, T.M, Neggers, S.J.C.M.M, Themmen, A.P.N, van der Lely, A-J, & Delhanty, P.J.D. (2014). Development of potent selective competitive-antagonists of the melanocortin type 2 receptor. Molecular and Cellular Endocrinology, 394(1-2), 99–104. doi:10.1016/j.mce.2014.07.003